Savara Inc Payments to Acquire Debt Securities, Available-for-sale
Savara Inc (SVRA) reported Payments to Acquire Debt Securities, Available-for-sale of $19.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- Savara Inc payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $127.24M, a 296.84% increase year-over-year.
- Savara Inc payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $22.93M, a 83.47% decline year-over-year.
- Savara Inc payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $39.66M, a 1052.51% increase year-over-year.
- Savara Inc payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $15.07M, a 50.91% decline year-over-year.
- Savara Inc payments to acquire debt securities, available-for-sale for fiscal 2025 was $204.90M, a 0.01% decline from fiscal 2024.
- Savara Inc payments to acquire debt securities, available-for-sale for fiscal 2024 was $204.92M, a 5.51% increase from fiscal 2023.
- Savara Inc payments to acquire debt securities, available-for-sale for fiscal 2023 was $194.22M, a 117.21% increase from fiscal 2022.
- Savara Inc payments to acquire debt securities, available-for-sale for fiscal 2022 was $89.42M, a 44.49% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.38M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $127.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $150.17M derived: sum of 2 quarters · filed 2026-03-13 | $189.83M derived: sum of 3 quarters · filed 2026-08-11 | $204.90M 10-K · filed 2026-03-13 |
| 2025-09-30 | $22.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $62.59M derived: sum of 2 quarters · filed 2026-08-11 | $77.66M 10-Q · filed 2025-11-12 | $109.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $39.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $54.73M 10-Q · filed 2026-08-11 | $86.79M derived: sum of 3 quarters · filed 2026-08-11 | $225.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $15.07M 10-Q · filed 2026-05-12 | $47.13M derived: sum of 2 quarters · filed 2026-05-12 | $185.85M derived: sum of 3 quarters · filed 2026-05-12 | $189.29M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $32.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $170.78M derived: sum of 2 quarters · filed 2026-03-13 | $174.22M derived: sum of 3 quarters · filed 2026-03-13 | $204.92M 10-K · filed 2026-03-13 |
| 2024-09-30 | $138.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $142.16M derived: sum of 2 quarters · filed 2025-11-12 | $172.85M 10-Q · filed 2025-11-12 | $211.66M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $34.14M 10-Q · filed 2025-08-13 | $72.94M derived: sum of 3 quarters · filed 2025-08-13 | $167.49M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $30.70M 10-Q · filed 2025-05-13 | $69.50M derived: sum of 2 quarters · filed 2025-05-13 | $164.04M derived: sum of 3 quarters · filed 2025-05-13 | $194.83M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $38.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $133.35M derived: sum of 2 quarters · filed 2025-03-27 | $164.13M derived: sum of 3 quarters · filed 2025-03-27 | $194.22M 10-K · filed 2025-03-27 |
| 2023-09-30 | $94.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $125.32M derived: sum of 2 quarters · filed 2024-11-12 | $155.41M 10-Q · filed 2024-11-12 | $228.83M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $30.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $60.87M 10-Q · filed 2024-08-12 | $134.28M derived: sum of 3 quarters · filed 2024-08-12 | $134.28M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $30.09M 10-Q · filed 2024-05-09 | $103.50M derived: sum of 2 quarters · filed 2024-05-09 | $103.50M derived: sum of 3 quarters · filed 2024-05-09 | $103.50M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $73.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $73.41M derived: sum of 2 quarters · filed 2024-03-07 | $73.41M derived: sum of 3 quarters · filed 2024-03-07 | $89.42M 10-K · filed 2024-03-07 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $16.00M 10-Q · filed 2023-11-09 | $38.53M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $16.00M 10-Q · filed 2023-08-10 | $38.53M derived: sum of 3 quarters · filed 2023-08-10 | $62.63M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $16.00M 10-Q · filed 2023-05-15 | $38.53M derived: sum of 2 quarters · filed 2023-05-15 | $62.63M derived: sum of 3 quarters · filed 2023-05-15 | $82.75M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $22.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $46.62M derived: sum of 2 quarters · filed 2023-03-30 | $66.75M derived: sum of 3 quarters · filed 2023-03-30 | $161.07M 10-K · filed 2023-03-30 |
| 2021-09-30 | $24.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $44.22M derived: sum of 2 quarters · filed 2022-11-10 | $138.54M 10-Q · filed 2022-11-10 | $154.47M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $20.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $114.44M 10-Q · filed 2022-08-11 | $130.37M derived: sum of 3 quarters · filed 2022-08-11 | $164.91M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $94.32M 10-Q · filed 2022-05-11 | $110.25M derived: sum of 2 quarters · filed 2022-05-11 | $144.79M derived: sum of 3 quarters · filed 2022-05-11 | $144.79M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $15.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $50.47M derived: sum of 2 quarters · filed 2022-03-30 | $50.47M derived: sum of 3 quarters · filed 2022-03-30 | $86.08M 10-K · filed 2022-03-30 |
| 2020-09-30 | $34.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $34.54M derived: sum of 2 quarters · filed 2021-11-12 | $70.16M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $35.61M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $35.61M 10-Q · filed 2021-05-13 | |||
| 2019-03-31 | $46.03M 10-Q · filed 2019-05-09 | $80.42M derived: sum of 2 quarters · filed 2019-05-09 | $143.81M derived: sum of 3 quarters · filed 2019-05-09 | $152.64M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-12-31 | $34.39M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $97.77M derived: sum of 2 quarters · filed 2019-03-13 | $106.60M derived: sum of 3 quarters · filed 2019-03-13 | $122.49M 10-K · filed 2019-03-13 |
| 2018-09-30 | $63.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $72.21M derived: sum of 2 quarters · filed 2018-11-07 | $88.10M 10-Q · filed 2018-11-07 | $131.52M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-06-30 | $8.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $24.72M 10-Q · filed 2018-08-09 | $68.14M derived: sum of 3 quarters · filed 2019-05-09 | |
| 2018-03-31 | $15.89M 10-Q · filed 2019-05-09 | $59.31M derived: sum of 2 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $43.42M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $76.86M 10-K · filed 2019-03-13 | ||
| 2017-09-30 | $33.44M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |